Skip to main content

Advertisement

SpringerLink
Log in

Imatinib in the treatment of solid tumours

  • Review
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

The extraordinary success of imatinib in gastrointestinal stromal tumors (GIST) represents a model for molecularly targeted therapy for other solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. In this article, we review recent advances in the clinical management of patients with GISTs treated with imatinib, but also of patients with dermatofibrosarcoma protuberans, chordoma, aggressive fibromatosis, and some other common solid tumors treated with this drug. We reviewed the knowledge of the molecular mechanisms that are basic to imatinib effects in these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buchdunger E, Cioffi CL, Law N et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-KIT and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139–145

    CAS  PubMed  Google Scholar 

  2. Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566

    Article  CAS  PubMed  Google Scholar 

  3. Dewar AL, Camnareri AC, Zannettino AC et al (2005) Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib. Blood 105:3127–3132

    Article  CAS  PubMed  Google Scholar 

  4. Heinrich MC, Griffith DJ, Druker BJ et al (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925–932

    CAS  PubMed  Google Scholar 

  5. Verweij J, Van Oosterom A, Blay JY et al (2003) Imatinib mesylate (STI 571 Glivec ®, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006–2011

    CAS  Google Scholar 

  6. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

    Article  CAS  PubMed  Google Scholar 

  7. Druker BJ (2003) Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 40(1):50–58

    Article  CAS  PubMed  Google Scholar 

  8. Went PT, Dirnhofer S, Bundi M et al (2004) Prevalence of KIT expression in human tumors. J Clin Oncol 22:4514–4422

    Article  CAS  PubMed  Google Scholar 

  9. Van der Zwan SM, Dematteo RP (2005) Gastrointestinal stromal tumor: 5 years later. Cancer 104:1781–1788

    Article  PubMed  CAS  Google Scholar 

  10. Nilsson B, Bumming P, Meis-Kindblom JM (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognosis in the imatinib mesylate era-a population-based study in western Sweden. Cancer 103:821–829

    Article  PubMed  Google Scholar 

  11. Joensuu H, Kindblom LG (2004) Gastrointestinal tromal tumors—a review. Acta Orthop Scand 75(suppl 4):287–289

    Google Scholar 

  12. Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269

    CAS  PubMed  Google Scholar 

  13. Kirsch R, Gao ZH, Ridell R (2007) Gastrointestinal stromal tumors: diagnostic challenges and practical approach to differential diagnosis. Adv Anat Pathol 14(4):261–285

    Article  PubMed  Google Scholar 

  14. Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459–465

    Article  PubMed  Google Scholar 

  15. Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710

    Article  CAS  PubMed  Google Scholar 

  16. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  CAS  PubMed  Google Scholar 

  17. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813–3825

    Article  CAS  PubMed  Google Scholar 

  18. Corless CL, Schroeder A, Griffith D et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357–5364

    Article  CAS  PubMed  Google Scholar 

  19. Dematteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58

    Article  CAS  PubMed  Google Scholar 

  20. D’amato G, Steinert DM, McAuliffe JC et al (2005) Update on the biology and therapy of gastrointestinal stromal tumor. Cancer Control 12:44–56

    PubMed  Google Scholar 

  21. Joensuu H, Fletcher C, Dimitrijevic S et al (2002) Management of malignant gastrointestinal stromal tumors. Lancet Oncol 3:655–664

    Article  CAS  PubMed  Google Scholar 

  22. Heinrich MC, Blanke CD, Druker BJ et al (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692–1703

    Article  CAS  PubMed  Google Scholar 

  23. Tuveson DA, Willis NA, Jacks T et al (2001) STI571 inactivation of the gastrointestinal stromal tumor c-kit oncoprotein: biological and clinical implications. Oncogene 20:5054–5058

    Article  CAS  PubMed  Google Scholar 

  24. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrocine kinase inhibitor STI571 in a patient with a metsatstic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056

    Article  CAS  PubMed  Google Scholar 

  25. Van Oosterom AT, Judson J, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423

    Article  PubMed  Google Scholar 

  26. Von Mehren M, Blanke C, Joensuu H et al (2002) High incidence or durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 21:403a

    Google Scholar 

  27. Verweij J, van Oosterom A, Blay JY et al (2003) Imatinib mesylate (STI-571, Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006–2011

    CAS  Google Scholar 

  28. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134

    Article  CAS  PubMed  Google Scholar 

  29. Benjamin RS, Rankin C, Fletcher C et al (2003) Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 22:814 for the Sarcoma Intergroup

    Google Scholar 

  30. Rankin C, von Mehren M, Blanke C et al (2004) Collaborating Investigators of the North American Sarcoma Intergroup. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST. Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 23:815

    Google Scholar 

  31. Byrd DG, Demetri GD, Joensuu H et al (2007) Evaluation of imatinib mesylate (IM) inpatients with large volume gastrointestinal stromal tumorsn(GISTs) Proc Am Soc Clin Oncol 558s (abstract 10054)

  32. Blanke C, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metsastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632

    Article  CAS  PubMed  Google Scholar 

  33. Blay JY, Bonvalot S, Casali P et al (2005) Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 March 2004, under the auspices of European Society for Medical Oncology. Ann Oncol 16:566–578

    Article  PubMed  Google Scholar 

  34. Demetri GD, Benjamin R, Blanke CD et al (2004) NCCN task force report: optimal management of patient with gastrointestinal stromal tumor (GIST)—expansion and update of NCCN clinical practice guidelines. J Natl Comp Cancer Network 2(suppl1):S1–S26

    Google Scholar 

  35. National Comprehensive Cancer Network (2006) Clinical practice guidelines in oncology. Soft tissue sarcoma. Version 3.2006 http://www.nccn.org/professionals/physicians_gls/PDFdfsp.pdf [accessed January 27, 2007]

  36. Debiec-Richter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with gastrointestinal stromal tumours. Eur J Cancer 42:1093–1103

    Article  CAS  Google Scholar 

  37. Heinrich MC, Shoemaker JS, Corless CL et al (2005) Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) Proc Am Soc Clin Oncol 2005:abstract 3s

  38. Zalcberg JR, Verweij J, Casali P et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751–1757

    Article  CAS  PubMed  Google Scholar 

  39. Van Glabbeke M, Owzar K, Rankin C et al (2007) GIST meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients (pts) [abstract] Proc Am Soc Clin Oncol 2007:abstr 10004

  40. Tamborini E, Bonadiman L, Greco A et al (2004) A new mutation in the ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294–299

    Article  CAS  PubMed  Google Scholar 

  41. Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. JCO 21(23):4342–4349

    Article  CAS  Google Scholar 

  42. Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764–4774

    Article  CAS  PubMed  Google Scholar 

  43. Debiec-Richter M, Dumez H, Judson I et al (2004) Use of c-KIT/PDGFRA mutational analysis to predict clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689–695

    Article  CAS  Google Scholar 

  44. Antonescu CR, Besmer P, Guo T et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182–4190

    Article  CAS  PubMed  Google Scholar 

  45. Debiec-Richter M, Cools J, Dumez H et al (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenteroloy 128:270–279

    Article  CAS  Google Scholar 

  46. Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumours comparing interruption versus continuation of treatment beyond 1 year: The French sarcoma Group. J Clin Oncol 25(9):1107–1113

    Article  CAS  PubMed  Google Scholar 

  47. Le Cesne A, Ray-Coquard I, Bui B et al (2007) Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after 3 years of treatment: A prospective randomized phase III trial of the French sarcoma Group. J Clin Oncol 2007 ASCO Annual Meeting Proceedings, Part I. 25(18S);abstract 10005

  48. DeMatteo R, Owzar K, Maki R et al (2007) ACOZOG AIAGS. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOZOG Z9001. J Clin Oncol 2007 ASCO Annual Meeting Proceedings, Part I. 25(18S);abstract 10079

  49. Bauer S, Hartmann JT, De Wit M et al (2005) Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117:316–325

    Article  CAS  PubMed  Google Scholar 

  50. Loughrey MB, Mitchell C, Mann GB et al (2005) Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 58:779–781

    Article  CAS  PubMed  Google Scholar 

  51. Raut CP, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325–2331

    Article  CAS  PubMed  Google Scholar 

  52. Din OS, Woll PJ (2008) Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Therapeutics and Clinical Risk Management 4(1):149–162

    CAS  PubMed  Google Scholar 

  53. Neuhaus SJ, Clark MA, Hayes AJ et al (2005) Surgery for gastrointestinal stromal tumour in the post-imatinib era. ANZ J Surg 75:165–172

    Article  PubMed  Google Scholar 

  54. Sakakura C, Hagiwara A, Soga K et al (2006) Long-term survival of a case with multiple liver metastases for duodenal gastrointestinal stromal tumor dramatically reduced by the treatment with imatinib and hepatectomy. World J Gastoenterol 12:2793–2797

    Google Scholar 

  55. Kosmadikis N, Visvardis EE, Kartsaklis P et al (2005) The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. Surg Oncol 14:75–84

    Article  Google Scholar 

  56. Scaife CL, Hunt KK, Patel SR et al (2003) Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 186:665–669

    Article  PubMed  Google Scholar 

  57. Bonvalot S, Eldweny H, Péchoux C et al (2006) Impact of surgery on advanced gastrointestinal stromal tumors (GIST). Ann Surg Oncol 13(12):1596–1603

    Article  CAS  PubMed  Google Scholar 

  58. Chang CK, Jacobs IA, Salti GI (2004) Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 30:341–345

    Article  CAS  PubMed  Google Scholar 

  59. Gloster HM Jr (1996) Dermatofibrosarcoma protuberans. J Am Acad Dermatol 35(3 Pt 1):335–374

    Google Scholar 

  60. Fioe M, Micelli R, Mussi C et al (2005) Dermatofibrosarcoma protuberans treated at single institution: a surgical disease with a high cure rate. J Clin Oncol 23:7669–7675

    Article  Google Scholar 

  61. Bowne WB, Antonescu CR, Leung DH et al (2000) Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 88:2711–2720

    Article  CAS  PubMed  Google Scholar 

  62. Mendenhall WM, Zlotecki RA, Scarborough MT (2004) Dermatofibrosarcoma protuberans. Cancer 101:2503–2508

    Article  PubMed  Google Scholar 

  63. McPeak CJ, Cruz T, Nicastri AD (1967) Dermatofibrosarcoma protuberans: an analysis of 86 cases–Five with metastasis/. Ann Surg 166:803–816

    Article  CAS  PubMed  Google Scholar 

  64. Szollosi Z, Nemes Z (2005) Transformed Dermatofibrosarcoma protuberans: a clinicopathological study of eight cases. J Clin Pathol 58:751–756

    Article  CAS  PubMed  Google Scholar 

  65. Mentzel T, Beham A, Katenkamp D et al (1998) Fibrosarcomatous (“high grade”) dermatofibrosarcoma protuberans : Clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 22:576–587

    Article  CAS  PubMed  Google Scholar 

  66. Naeem R, Lux ML, Huang SF et al (1995) Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 147:1553–1558

    CAS  PubMed  Google Scholar 

  67. Sanberg AA, Bridge JA (2003) Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 140:1–12

    Article  Google Scholar 

  68. Simon MP, Pedeutour F, Sirvent N et al (1997) Deregulation of the platelet–derived growth factor B-chain gene via fusion with collagen COL1A1 in Dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 15:95–98

    Article  CAS  PubMed  Google Scholar 

  69. Heldin CH, Ostman A, Ronnstrand L (1998) Signal transduction via platelet-derived growth factor receptors. Biochem Biophys Acta 1378:F79–113

    CAS  PubMed  Google Scholar 

  70. O’Brien KP, Seroussi E, Dal Cin P et al (1998) Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDFGB gene in Dermatofibrosarcoma protuberans and giant-cell fibroblastomas. Genes Chromosomes Cancer 23:187–193

    Article  PubMed  Google Scholar 

  71. Wang J, Hisaoka M, Shimajiri S et al (1999) Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription-polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 8:113–119

    Article  CAS  PubMed  Google Scholar 

  72. Shimizu A, O’Brien KP, Sjoblom T et al (1999) The dermatofibrosarcoma protuberans–associated collagen type I alpha1/platelet-derived factor (PDGF) B-chain fusion gene generates a transforming protein that is proceeded to functional PDGF-BB. Cancer Res 59:3719–3723

    CAS  PubMed  Google Scholar 

  73. Gloster HM Jr., Harris KR, Roenigk RK (1996) A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of Dermatofibrosarcoma protuberans. J Am Acad Dermatol 35:82–87

    Article  PubMed  Google Scholar 

  74. Khatri VP, Galante JM, Bold RJ et al (2003) Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol. 10:1118–1122

    Article  PubMed  Google Scholar 

  75. Parker TL, Zitelli JA (1995) Surgical margins for excision of Dermatofibrosarcoma protuberans. J Am Acad Dermatol 32(2 Pt 1):233–236

    Article  CAS  PubMed  Google Scholar 

  76. Ballo MT, Zagars GK, Pisters P et al (1998) The role of radiation therapy in the management of Dermatofibrosarcoma protuberans. Am J Clin Oncol Biol Phys 40:823–827

    Article  CAS  Google Scholar 

  77. Dagan R, Morris CG, Zlotecki RA et al (2005) Radiotherapy in the treatment of Dermatofibrosarcoma protuberans of the trunk and extremities. Am J Clin Oncol 28:537–539

    Article  PubMed  Google Scholar 

  78. Greco A, Roccato E, Miranda C et al (2001) Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 92:354–360

    Article  CAS  PubMed  Google Scholar 

  79. Sjoblom T, Shimizu A, O’Brien KP et al (2001) Growth inhibition of Dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61:5778–5783

    CAS  PubMed  Google Scholar 

  80. Maki RG, Awan RA, Dixon RH et al (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from Dermatofibrosarcoma protuberans. Int J Cancer 100:623–626

    Article  CAS  PubMed  Google Scholar 

  81. Rubin BP, Schuetze SM, Eary JF et al (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosrcoma protuberans. J Clin Oncol 20:3586–3591

    Article  CAS  PubMed  Google Scholar 

  82. Mizutani K, Tamada Y, Hara K et al (2004) Imatinib mesylate inhibited the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 151:235–237

    Article  CAS  PubMed  Google Scholar 

  83. Labropoulos SV, Fletcher JA, Oliveira AM et al (2005) Sustained complete remission of metastatic Dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 16:461–466

    Article  CAS  PubMed  Google Scholar 

  84. Price V, Zielenska M, Smith C et al (2004) Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors. (GIST)[abstract]Proc Am Soc Clin Oncol 23:804

    Google Scholar 

  85. Mc Arthur GA, Demetri GD, van Oosterom A et al (2005) Molecular and clinical analysis of locally advanced Dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23:866–873

    Article  CAS  Google Scholar 

  86. Heinrich MC, Joensuu H, Demetri GD et al (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 14(9):2717–2125

    Article  CAS  PubMed  Google Scholar 

  87. Imatinib in Dermatofibrosarcoma protuberans (DFSP): sponsored by Dermatologic Cooperative Oncology Group. Clinical Trials.gov identifier: NCT00122473

  88. Neoadjuvant imatinib in Dermatofibrosarcoma protuberans: sponsored by Sarcoma Alliance for Research Trough Collaboration ClinicalTrials.gov identifier: NCT00243191

  89. A short course of neoadjuvant Gleevec (imatinib mesylate) in dermatofibrosarcoma protuberans sponsored by University of Michigan Cancer Center. ClinicalTrials. govidentifier: NCT00176709

  90. Imatinib mesylate in treating patients with locally advanced or metastatic Dermatofibrosarcoma protuberans or giant cell fibroblastoma: sponsored by European Organization for Research and Treatment of Cancer. ClinicalTrials. govidentifier: NCT00085375

  91. Heffelfinger MJ, Dahlin DC, MacCarty CS et al (1973) Chordomas and cartilaginous tumors at the skull case. Cancer 32:410–420

    Article  CAS  PubMed  Google Scholar 

  92. Casali P, Stacchiotti S, Sangalli C et al (2007) Chordoma. Curr Opinion Oncol 19(4):367–370

    Article  Google Scholar 

  93. Azzarelli A, Quagliuolo V, Cesaroli S et al (1988) Chordoma: natural history and treatment results of 33 cases. J Surg Oncol 37:185–191

    Article  CAS  PubMed  Google Scholar 

  94. Scimecca PG, James-Herry AG, Black KS et al (1996) Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol 18:237–240

    Article  Google Scholar 

  95. Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in Chordoma. Cancer 101:2086–2097

    Article  CAS  PubMed  Google Scholar 

  96. Casali PG, Stacchiotti A, Messina E et al (2006) Imatinib mesylate in 18 advanced chordoma patients. J Clin Oncol 2006, Proc Am Soc Clin Oncol 819s:abstract 9012

  97. Tamborini E, Miselli F, Negri T et al (2006) Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR)B, PDGFRA, and KIT Receptors in Chordomas. Clin Cancer Res 12(23):6920–6928

    Article  CAS  PubMed  Google Scholar 

  98. Burger H, den Bakker MA, Kros JM et al (2005) Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 4(11):1270–1274

    CAS  PubMed  Google Scholar 

  99. Stacchiotti S, Ferrari V, Ferraresi G et al (2007) Imatinib mesylate in advanced chordoma: A multicenter phase II study. J Clin Oncol 545s:abstract 10003

  100. Stacchiotti S, Grosso F, Dileo P et al (2006) Antitumor activity of imatinib plus cisplatin in two patients with advanced chordoma. Proc. 12th Annual Connective Tissue Oncology Society Meeting 2006:abstract 425

  101. Casali PG, Stacchiotti S, Grossso F et al (2007) Adding cisplatin (CDDP) to imatinib (IM) re-establishes tumor response following secondary resistance to IM in advanced chordoma. J Clin Oncol 55s:abstract 10038

    Google Scholar 

  102. Marrari A, Stacchiotto S, Crippa F et al (2008) Effect of adding sirolimus (s) to imatinib (im) on tumor response following secondary resistance to imatinib (im) in advanced chordoma. J Clin Oncol 563s: abstract 10541

  103. Alman BA, Pajerski ME, Diaz-Cano S et al (1997) Aggressive fibromatosis (desmoid tumor) is a monoclonal dosroder. Diag Mol Pathol 6:98–101

    Article  CAS  Google Scholar 

  104. Hoos A, Lewis JJ, Antonescu CR et al (2001) Characterization of molecular abnormalities in human fibroblastic neoplasms: A model for genotype-phenotype association in soft tissue tumors. Cancer Res 61:3171–3175

    CAS  PubMed  Google Scholar 

  105. Gardner EJ (1962) Follow up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. Am J Hum Genet 14:376–390

    CAS  PubMed  Google Scholar 

  106. Hayry P, Reitamo JJ, Totterman S et al (1982) The desmoid tumor: analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol 77:674–680

    CAS  PubMed  Google Scholar 

  107. Li M, Cordon-Cardo C, Gerald WL et al (1996) Desmoid fibromatosis is a clonal process. Human Pathol 27:939–943

    Article  CAS  Google Scholar 

  108. Ballo MT, Zagars GK, Pollack A et al (1999) Desmoid tumor: prognostic factors and ourcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17:158–167

    CAS  PubMed  Google Scholar 

  109. Klein WA, Miller HH, Anderson M et al (1987) The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 60:2863–2868

    Article  CAS  PubMed  Google Scholar 

  110. Wadell WR, Gerner RE, Reich MP (1991) Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. Am J Surg 161:416–421

    Article  Google Scholar 

  111. Wadell WR, Kirsc WM (1991) Testolactone, sulindac, warfarin, and vitamin K for unresectable desmoid tumors. Am J Surg 161:416–421

    Article  Google Scholar 

  112. Bauernhofer T, Stoger H, Schmid M et al (1996) Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 77:1061–1065

    Article  CAS  PubMed  Google Scholar 

  113. Tonelli F, Valanzano R, Brandi ML (1994) Pharmacologic treatment of desmoid tumors in familial adenomatous popyposis: results of an in vitro study. Surgery 115:473–479

    CAS  PubMed  Google Scholar 

  114. Brooks MD, Ebbs SR, Colletta AA et al (1992) Desmoid tumors treated with tripenylethylenes. Eur J cancer 28A:1014–1018

    Article  CAS  PubMed  Google Scholar 

  115. Lanori A (1983) Effect of progesterone on desmoid tumors (aggressive fibromatosis). N Engl J Med 309:1523

    Google Scholar 

  116. Acker JC, Bossen EH, Halperin EC (1993) The management of desmoid tumors. Int J Radiat Oncol Phys 26:851–858

    Article  CAS  Google Scholar 

  117. Fernberg JO, Brosjo O, Larsson O et al (1999) Interferon-induced remission in aggressive fibromatosis of the lower extremity. Acta Oncol 38:971–972

    Article  CAS  PubMed  Google Scholar 

  118. Schnitzler M, Cohen Z, Blackstein M (1997) Chemotherapy for desmoid tumor in association with familial adenomatous polyposis. Dis Colon Rectum 40:798–801

    Article  CAS  PubMed  Google Scholar 

  119. Seiter K, Kemeny N (1993) Successful treatment of a desmoid tumor with doxorubicin. Cancer 71:2242–2244

    Article  CAS  PubMed  Google Scholar 

  120. Patel SR, Evans HL, Benjamin RS (1993) Combination chemotherapy in adult desmoid tumors. Cancer 72:3244–3247

    Article  CAS  PubMed  Google Scholar 

  121. Weiss AJ, Horowitz S, Lackman RD (1999) Therapy of desmoid tumors and fibormatosis using vonirelbine. Am J Clin Oncol 22:193–195

    Article  CAS  PubMed  Google Scholar 

  122. Skapiec SX, Hawk BJ, Hoffer FA et al (1998) Combination chemotherapy using vinorelbine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 16:3021–3027

    Google Scholar 

  123. Mace J, Biermann JS, Sondak V et al (2002) Response to extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373–2379

    Article  CAS  PubMed  Google Scholar 

  124. Heinrich MC, McArthur GA, Demetri GD et al (2006) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatis (desmoid tumor). J Clin Oncol 24:1195–1202

    Article  CAS  PubMed  Google Scholar 

  125. Liegl B, Leithner A, Bauernhaufer T et al (2006) Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine linase inhibitors in c-kit negative desmoid tumours? Histopathology 49:576–581

    Article  CAS  PubMed  Google Scholar 

  126. Penel N, Le Cesne A, Bui B et al (2007) Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) falling local treatment. A phase II trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 523s:abstract 9516

  127. Churgh R, Maki RG, Thomas DG et al (2007) A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. Proc Am Soc Clin Oncol 523s:abstract 9515

  128. Parsons JT, Mendenhall WM, Stringer SP et al (1996) Management of minor salivary gland carcinomas. Int J Radiat Oncol Biol Phys 35:443–454

    Article  CAS  PubMed  Google Scholar 

  129. Vermorken JB, Verweij J, de Mulder PH et al (1993) Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC Had and neck cancer Cooperative Group. Ann Oncol 4:785–788

    CAS  PubMed  Google Scholar 

  130. Verweij J, de Mulder PH, de Graeff A et al (1996) Phase II study on mitoxantrone in adenoid cystic carcinoma of the head and neck. Ann Oncol 7:867–869

    CAS  PubMed  Google Scholar 

  131. Hill ME, Constenla DO, A’Hern RP et al (1997) Cisplatin and 5-Fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 33:275–278

    Article  CAS  PubMed  Google Scholar 

  132. Airoldi M, Fornari G, Pedani F et al (2000) Paclitaxel and carboplatin for recurrent salivary gland malignancies. Cancer Res 20:3781–3784

    CAS  Google Scholar 

  133. Airoldi M, Pedani F, Succo G et al (2001) Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91:541–547

    Article  CAS  PubMed  Google Scholar 

  134. Jeng YM, Lin CY, Hsu HC (2000) Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Letter 154:107–111

    Article  CAS  Google Scholar 

  135. Holst VA, Marshall CE, Moskaluk CA, Frierson Jr HF (1999) KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12:956–960

    CAS  PubMed  Google Scholar 

  136. Alcedo JC, Fabrega JM, Arosemena JR et al (2004) Imatinib mesylta as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head neck 26:829–831

    Article  PubMed  Google Scholar 

  137. Faivre S, Raymond E, Casiraghi O et al (2005) Imatinib mesylate can induce objective response in progressing highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23:6271–6273

    Article  PubMed  Google Scholar 

  138. Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate with adenoid cystic cancers of the salivary glands expressing c-kit; a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23:585–590

    Article  CAS  PubMed  Google Scholar 

  139. Pfeffer MR, Talmi Y, Catane R et al (2007) A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43:33–36

    Article  CAS  PubMed  Google Scholar 

  140. Curtin JA, Busam K, Pinkel D et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346

    Article  CAS  PubMed  Google Scholar 

  141. Wyman K, Atkins MB, Prieto V et al (2006) Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106:2005–2011

    Article  CAS  PubMed  Google Scholar 

  142. Ugurel S, Hildenbrand R, Zimpfer A et al (2005) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398–1405

    Article  CAS  PubMed  Google Scholar 

  143. Kim KB, Eton O, Davis DW et al (2008) Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99:734–740

    Article  CAS  PubMed  Google Scholar 

  144. Hwang RF, Yokoi K, Bucana CD et al (2003) Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9:6534–6544

    CAS  PubMed  Google Scholar 

  145. Mathew P, Fidler IJ, Logothetis CJ (2004) Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 31:24–29

    Article  CAS  PubMed  Google Scholar 

  146. Pietras K, Rubin K, Sjoblom T et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476–5484

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

No funds were received in support of this study.

Author information

Authors and Affiliations

  1. Hôpital La timone, Centre Hospitalier Universitaire de l’Assistance Publique des Hôpitaux de Marseille, 264 rue Saint Pierre, 13385, Marseille, France

    Florence Duffaud

  2. Institut Gustave-Roussy, Villejuif, France

    Axel Le Cesne

Authors
  1. Florence Duffaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Le Cesne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florence Duffaud.

Additional information

Article first published in Des Guetz G, Blay J-Y (eds.) (2008) Les thérapies ciblées. Springer, France. Copyright Springer-Verlag France 2008. Translated and reprinted with permission.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duffaud, F., Le Cesne, A. Imatinib in the treatment of solid tumours. Targ Oncol 4, 45–56 (2009). https://doi.org/10.1007/s11523-008-0101-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-008-0101-x

Keywords

Search

Navigation